Search Results - "Mackowski, Mia"

Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study by Hershey, Andrew D., Paiva da Silva Lima, Gabriel, Pannacciulli, Nicola, Mackowski, Mia, Koukakis, Reija, McVige, Jennifer Williams

“…Erenumab, a fully human monoclonal antibody targeting the calcitonin gene‐related peptide receptor, is efficacious and safe for prevention of attacks of…”
Get full text

Pharmacokinetics, Disposition, and Biotransformation of [ 14 C]Omecamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral Dose by Trivedi, Ashit, Wahlstrom, Jan, Mackowski, Mia, Dutta, Sandeep, Lee, Edward

“…Omecamtiv mecarbil (OM) is a novel cardiac myosin activator that is currently in clinical development for the treatment of heart failure. The absorption and…”
Get full text

Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects by Trivedi, Ashit, Mackowski, Mia, Jafarinasabian, Pegah, Zhang, Hanze, Flach, Stephen, Terminello, Bianca, Bhatia, Ajay, Dutta, Sandeep, Lee, Edward

“…Background and Objective Omecamtiv mecarbil (OM) is a cardiac myosin activator under clinical development for the treatment of heart failure. Two…”
Get full text

Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator by Trivedi, Ashit, Oberoi, Rajneet K., Mackowski, Mia, Jafarinasabian, Pegah, Zhang, Hanze, Flach, Stephen, Simiens, Mary Ann, Terminello, Bianca, Abbasi, Siddique, Dutta, Sandeep, Lee, Edward

“…Omecamtiv mecarbil (OM) is a cardiac myosin activator in clinical development for the treatment of heart failure. The effect of food on the pharmacokinetics…”
Get full text

Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects by Trivedi, Ashit, Malik, Fady I., Mackowski, Mia, Hutton, Shauna, Aoki, Makoto, Abbasi, Siddique, Dutta, Sandeep, Lee, Edward

“…Background and Objectives Omecamtiv mecarbil (OM) is a cardiac myosin activator under development for the treatment of heart failure. The pharmacokinetics of…”
Get full text

Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Omecamtiv Mecarbil by Trivedi, Ashit, Oberoi, Rajneet K., Mackowski, Mia, Jafarinasabian, Pegah, Zhang, Hanze, Flach, Stephen, Hutton, Shauna, Abbasi, Siddique, Dutta, Sandeep, Lee, Edward

“…Omecamtiv mecarbil (OM) is a novel selective cardiac myosin activator under investigation for the treatment of heart failure with reduced ejection fraction. OM…”
Get full text